American journal of cardiovascular drugs : drugs, devices, and other interventions
-
Am J Cardiovasc Drugs · Aug 2014
ReviewDyspnea and reversibility profile of P2Y₁₂ antagonists: systematic review of new antiplatelet drugs.
Dyspnea has been consecutively reported in some trials evaluating new P2Y₁₂ inhibitors. ⋯ The reversible P2Y₁₂ antagonists ticagrelor, cangrelor, and elinogrel have an increased incidence of dyspnea in increasing order when compared with irreversible P2Y₁₂ inhibitors such as clopidogrel or prasugrel.